TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
ImmuneBiotech Medical Sweden AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
255
|
217
|
161 |
| Financial expenses |
0
|
0
|
1 |
| Earnings before taxes |
-672
|
-519
|
-550 |
| EBITDA |
-692
|
-509
|
-534 |
| Total assets |
1,340
|
2,000
|
737 |
| Current assets |
1,335
|
1,984
|
706 |
| Current liabilities |
75
|
69
|
47 |
| Equity capital |
1,265
|
1,931
|
690 |
| - share capital |
7
|
7
|
7 |
| Employees (average) |
3
|
2
|
1 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
94.4%
|
96.6%
|
93.6% |
| Turnover per employee |
85
|
108
|
161 |
| Profit as a percentage of turnover |
-263.5%
|
-239.2%
|
-341.6% |
| Return on assets (ROA) |
-50.1%
|
-26.0%
|
-74.5% |
| Current ratio |
1780.0%
|
2875.4%
|
1502.1% |
| Return on equity (ROE) |
-53.1%
|
-26.9%
|
-79.7% |
| Change turnover |
37
|
69
|
93 |
| Change turnover % |
17%
|
47%
|
138% |
| Chg. No. of employees |
1
|
1
|
0 |
| Chg. No. of employees % |
50%
|
100%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.